Clinical Policy: Anti-Inhibitor Coagulant Complex (Feiba)
Reference Number: ERX.SPMN.199
Effective Date: 01/17
Last Review Date:

See Important Reminder at the end of this policy for important regulatory and legal information.

Policy/Criteria
It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that anti-inhibitor coagulant complex (Feiba®) is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Hemophilia A and B (must meet all):
      1. Prescribed by or in consultation with a hematologist;
      2. Diagnosis of hemophilia A or B with inhibitors;
      3. Medication will be used for any of the following:
         a. Control and prevention of bleeding episodes;
         b. Perioperative management;
         c. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

         Approval duration: 3 months (bleeding episodes/surgery)
         6 months (prophylaxis)

   B. Other diagnoses/indications: Refer to ERX.SPMN.16 - Global Biopharm Policy.

II. Continued Approval
   A. Hemophilia A and B (must meet all):
      1. Currently receiving medication via health plan benefit or member has previously met all initial approval criteria.

         Approval duration: 3 months (bleeding episodes/surgery)
         6 months (prophylaxis)

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy; or
      2. Refer to ERX.SPMN.16 - Global Biopharm Policy.

Background
Description/Mechanism of Action:
Multiple interactions of the components in Feiba (anti-inhibitor coagulant complex) restore the impaired thrombin generation of hemophilia patients with inhibitors. In vitro, anti-inhibitor coagulant complex shortens the activated partial thromboplastin time of plasma containing factor VIII inhibitor.
FORMULATIONS:
Solution Reconstituted, Intravenous:
Feiba (prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity))

FDA Approved Indications:
Feiba is indicated for use in hemophilia A and B patients with inhibitors for:
- Control and prevention of bleeding episodes;
- Perioperative management;
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
Limitations of use: Feiba is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J7198</td>
<td>Antiinhibitor, per IU</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals
Policy created. 12/16 01/17

References

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.
CLINICAL POLICY
Anti-inhibitor coagulant complex

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2016 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.